At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 302 enrolled
Drug / intervention
BEMA Buprenorphinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 52-Week, Open Label, Longterm Treatment Evaluation of the Safety and Efficacy of BEMA® Buprenorphine in Subjects With Moderate to Severe Chronic Pain
In Brief
A Phase 3 clinical trial evaluating BEMA Buprenorphine for Pain and 3 related conditions. Completed, enrolled 302 participants across 26 sites.
Detailed Summary
The purpose of this study is to determine whether BEMA Buprenorphine is safe in the treatment of chronic pain.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain, Low Back Pain, Osteoarthritis, Neuropathic Pain
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2011
Enrollment StartMar 2011
Primary CompletionAug 2012
TodayJul 2026
First PostedFeb 18, 2011
Enrollment StartMar 1, 2011
Primary CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 15.4 years ago
Interventions
BEMA Buprenorphinedrug
buccal soluble film; applied to the buccal mucosa twice daily